OKYO OKYO Pharma Limited Ordinary Shares
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 5
- List Date
- 2022-05-17
- CIK
- 0001849296
- Homepage
- https://www.okyopharma.com
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The co…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | 26.00% | -23.71% | -6.19% | -8.07% | -2.99% |
| Feb | -- | -0.89% | -10.74% | 18.86% | -18.18% | -2.74% |
| Mar | -- | -24.66% | 2.05% | 0.79% | -9.04% | -7.71% |
| Apr | -- | -22.70% | 2.04% | 34.32% | -6.02% | 1.91% |
| May | -43.37% | 10.64% | -0.67% | 18.21% | 3.31% | -2.38% |
| Jun | 6.60% | -25.62% | -16.78% | 46.86% | -12.28% | -0.24% |
| Jul | 6.83% | 66.96% | -0.81% | 3.45% | 12.35% | 17.76% |
| Aug | 10.54% | 24.07% | 20.60% | -24.19% | -8.98% | 4.41% |
| Sep | -3.31% | -7.04% | -11.30% | -13.79% | -14.57% | -10.00% |
| Oct | -15.93% | -12.63% | 13.99% | 36.32% | 7.46%* | 5.84% |
| Nov | -8.80% | 1.87% | -14.88% | -27.41% | -- | -12.30% |
| Dec | -4.98% | 6.31% | 10.57% | 11.29% | -- | 5.80% |
| Total | -49.78% | 9.05% | -33.27% | 95.12% | -45.30% | -4.84% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
OKYO Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
High volatility - stock moves more than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $17K | #3103 of 3138 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
OKYO Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
OKYO Insider Trading (Form 4)
Latest: 2026-08-07| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-07 | Gary S Jacob | CHIEF DEVELOPMENT OFFICER | Buy (P) | +3,500 | $1.40 | $4.9K | EDGAR |
| 2026-08-07 | Rajkumar V. Patil | Chief Scientific Officer | Buy (P) | +3,363 | $1.49 | $5.0K | EDGAR |
| 2026-08-07 | John P Brancaccio | Director | Buy (P) | +5,000 | $1.48 | $7.4K | EDGAR |
| 2026-08-07 | Robert John Dempsey | CHIEF EXECUTIVE OFFICER | Buy (P) | +15,000 | $1.54 | $23.1K | EDGAR |
| 2026-08-07 | Gabriele M Cerrone | Director | Buy (P) | +25,000 | $1.40 | $35.0K | EDGAR |
| 2026-08-07 | Flavio Mantelli | CHIEF MEDICAL OFFICER | Buy (P) | +20,000 | $1.40 | $28.0K | EDGAR |
| 2026-08-07 | Gabriele M Cerrone | Director | Buy (P) | +22,500 | $1.45 | $32.6K | EDGAR |
| 2026-08-07 | Gary S Jacob | CHIEF DEVELOPMENT OFFICER | Buy (P) | +3,500 | $1.40 | $4.9K | EDGAR |
| 2026-08-07 | Rajkumar V. Patil | Chief Scientific Officer | Buy (P) | +3,363 | $1.49 | $5.0K | EDGAR |
| 2026-08-07 | Flavio Mantelli | CHIEF MEDICAL OFFICER | Buy (P) | +20,000 | $1.40 | $28.0K | EDGAR |
| 2026-08-07 | Gabriele M Cerrone | Director | Buy (P) | +22,500 | $1.45 | $32.6K | EDGAR |
| 2026-08-07 | Gabriele M Cerrone | Director | Buy (P) | +25,000 | $1.40 | $35.0K | EDGAR |
| 2026-08-07 | John P Brancaccio | Director | Buy (P) | +5,000 | $1.48 | $7.4K | EDGAR |
| 2026-08-07 | Robert John Dempsey | CHIEF EXECUTIVE OFFICER | Buy (P) | +15,000 | $1.54 | $23.1K | EDGAR |
| 2026-07-29 | Rajkumar V. Patil | Chief Scientific Officer | Award (A) | +3,363 | $1.49 | $5.0K | EDGAR |
OKYO Insider Holdings
6 insiders · @ $1.44| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Gabriele M Cerrone | Director | 10,851,416 | $15.63M | $919.5K | 12 | 2026-08-07 |
| 2 | Gary S Jacob | CHIEF DEVELOPMENT OFFICER | 112,420 | $161.9K | $59.8K | 4 | 2026-08-07 |
| 3 | John P Brancaccio | Director | 35,201 | $50.7K | $39.8K | 5 | 2026-08-07 |
| 4 | Rajkumar V. Patil | Chief Scientific Officer | 20,030 | $28.8K | $10.0K | 3 | 2026-08-07 |
| 5 | Flavio Mantelli | CHIEF MEDICAL OFFICER | 20,000 | $28.8K | $56.0K | 3 | 2026-08-07 |
| 6 | Robert John Dempsey | CHIEF EXECUTIVE OFFICER | 15,000 | $21.6K | $46.2K | 3 | 2026-08-07 |
OKYO Board & Officers
As of SEC filings through Aug 7, 2026Directors 6
- Bernard Denoyer · since May 16, 2022
- Gabriele M Cerrone · since May 16, 2022
- Gary S Jacob · since May 16, 2022
- John P Brancaccio · since May 16, 2022
- Willy Jules Simon · since May 16, 2022
- Robert John Dempsey · since Mar 18, 2026
Officers 5
- Robert John Dempsey · Chief Executive Officer · since Mar 18, 2026
- Keeren Rameshchandra Shah · Chief Financial Officer · since Mar 18, 2026
- Flavio Mantelli · Chief Medical Officer · since Mar 18, 2026
- Gary S Jacob · Chief Development Officer · listed since Mar 2026
- Rajkumar V. Patil · Chief Scientific Officer · since Mar 18, 2026
10% owners 1
- Gabriele M Cerrone · listed since Mar 2026
Changes in the last 10 years (20)
| Mar 18, 2026 | Robert John Dempsey became a director |
| Mar 18, 2026 | Robert John Dempsey became Chief Executive Officer |
| Mar 18, 2026 | Rajkumar V. Patil became Chief Scientific Officer |
| Mar 18, 2026 | Keeren Rameshchandra Shah became Chief Financial Officer |
| Mar 18, 2026 | Gary S Jacob listed as Chief Development Officer (previously Chief Executive Officer) in SEC filings |
| Mar 18, 2026 | Gabriele M Cerrone no longer listed as Executive Chairman in SEC filings |
| Mar 18, 2026 | Gabriele M Cerrone first listed as a 10% owner in an SEC filing |
| Mar 18, 2026 | Flavio Mantelli became Chief Medical Officer |
| May 20, 2022 | Gabriele M Cerrone no longer listed as a 10% owner in SEC filings |
| May 20, 2022 | Gabriele M Cerrone listed as Executive Chairman (previously Non-Executive Chairman) in SEC filings |
| May 18, 2022 | Gabriele M Cerrone listed as Non-Executive Chairman (previously Executive Chairman) in SEC filings |
| May 16, 2022 | Willy Jules Simon became a director |
| May 16, 2022 | Keeren Shah became Chief Financial Officer |
| May 16, 2022 | John P Brancaccio became a director |
| May 16, 2022 | Gary S Jacob became a director |
| May 16, 2022 | Gary S Jacob became Chief Executive Officer |
| May 16, 2022 | Gabriele M Cerrone became a director |
| May 16, 2022 | Gabriele M Cerrone became a 10% owner |
| May 16, 2022 | Gabriele M Cerrone became Executive Chairman |
| May 16, 2022 | Bernard Denoyer became a director |
Not reported recently (1)
- Keeren Shah · Last reported as Chief Financial Officer in an SEC filing dated May 16, 2022
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.